Middle East & Africa Viscosupplementation Market Research Report - Segmented By Product Type, End-User and Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2024 to 2029)

Updated On: January, 2024
ID: 11793
Pages: 100

MEA Viscosupplementation Market Size (2023 to 2028)

The viscosupplementation market in the Middle East and Africa is estimated to grow at a CAGR of 7.71% during the forecast period and the market size is expected to rise from USD 260 million in 2023 to USD 380 million by 2028.

The growing aging population across the MEA region is contributing significantly to the viscosupplementation market in the Middle East and Africa. Most older people are suffering from osteoarthritis disorder due to increasing age and changing body functionality with regard to aging. This disease increases joint pain, swelling, and inflammation of the synovial spaces. Most older people are interested in taking the treatment at home without going anywhere as they feel comfortable and secure taking the treatment at home. Healthcare professionals and skilled nurses provide treatment by injecting medication at specified locations of the body in order to regain the fluid in the joint and reduce the pain. Obesity or heavy weight is also one of the reasons for joint pains among the population. Due to the rapidly changing lifestyle, increasing consumption of junk food and beverages like soft and hard drinks are the main reasons for increasing obesity cases. Since the early '40s, more people have suffered from joint disorders due to a lack of healthy diet and exercise and therefore prefer viscosupplementation treatments to help recover the health of the joints.

The growing adoption of non-surgical treatment to treat osteoarthritis is promoting the viscosupplementation market growth in MEA. Most people in recent years do not prefer to undergo surgeries due to the fear of complications after the surgery. As viscosupplementation treatment is not a surgical procedure and it only delivers injections at certain regular intervals to reduce pain and swelling people tend to prefer the procedure over surgery.

The growing R&D activities around hyaluronic acid are fuelling the growth rate of the MEA viscosupplementation market. Researchers are increasing their focus on developing drugs based on the previously available data and adding some of the new drugs to the existing ones to reduce the side effects of the knee, elbow, and other pain-related disorders drugs.

However, lack of awareness of the viscosupplementation treatment in rural areas is the major restrain the market growth. Furthermore, the high cost of the injection and the regulatory issues also hamper the market growth. In addition, side effects after the treatment, such as redness, itching, and swelling, impede market growth.

This research report on the Middle East and Africa viscosupplementation market has been segmented and sub-segmented into the following categories:

By Product:

  • Single Injection
  • Three Injection
  • Five Injection

By End-Use:

  • Hospitals
  • Orthopedic Clinic/ Ambulatory Surgical Centers (ASCs)

By Country:

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

Geographically, the Middle East and Africa is anticipated to account for a substantial share of the worldwide market during the forecast period due to a rise in hip osteoarthritis among populations of the region. Over the last three decades, cases have been increasing in Saudi Arabia and UAE. As a result, the government has increased its investment in developing drugs for viscosupplementation treatment.

The market in Saudi Arabia is expected to hold a major share of the regional market in the coming years owing to the increasing approval of drugs and the adoption of products to manage orthopedic disorders. An estimated 30% of the people in Saudi Arabia suffer from different joint problems that use viscosupplementation treatment to relieve pain. Hyaluronic acid in different forms is used in the injections, which are administered for the treatment of arthritic problems. Additionally, researchers have proved that hyaluronic acid is safe and effective in reducing pain and improving movement flexibility.

The market in UAE is estimated to grow at a healthy CAGR during the forecast period. The increasing adoption of hyaluronic acid-based drugs for the treatment of arthritis in many hospitals and clinics demands market growth in this region. The government also conducted an awareness program about the viscosupplementation treatment and how it can be taken based on the severity of the problem. In addition, the availability of injections in offline and online stores in this region also supports market growth.


Sanofi S.A., Zimmer Biomet Holdings Inc., Bioventus LLC, Anika Therapeutics Inc., Fidia Farmaceutici S.p.A., Ferring B.V., Seikagaku Corporation, Chungai Pharmaceutical Co., Ltd., OrthogenRx Inc., and Mylan N.V. are a few of the promising companies operating in the MEA viscosupplementation market.

Please wait. . . . Your request is being processed

Frequently Asked Questions

What is the size of the MEA Viscosupplementation Market?

The MEA viscosupplementation market size was valued at USD 220 million in 2022.

Who are the key players in the MEA Viscosupplementation Market?

Sanofi, Zimmer Biomet, Seikagaku Corporation, Bioventus, and Ferring Pharmaceuticals are some of the leading companies in the MEA viscosupplementation market.

Which countries are driving the growth of the MEA Viscosupplementation Market?

Saudi Arabia, the United Arab Emirates (UAE), and South Africa are the major regional markets in the MEA region.

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1200

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample